ACXP · Acurx Pharmaceuticals, Inc.
$1.42
+0.02 (+1.43%)
At close · Sep 4
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 13, 2026
Market Cap
$7.48M
Shares
5.27M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$7.97M
+43.5%
FY2025
Diluted EPS
-$5.32
+69.5%
FY2025
Operating Cash Flow
-$6.79M
+34.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $2.12M | $1.83M | $5.4M | $6.04M | $4.75M | $2.03M | $2.2M | |
| $5.54M | $6.26M | $8.72M | $8.53M | $7.34M | $10.78M | $2.4M | |
| — | — | — | — | — | $208.27K | — | |
| $7.67M | $8.09M | $14.12M | $14.58M | $12.09M | $12.81M | $4.6M | |
| -$7.67M | -$8.09M | -$14.12M | — | — | — | — | |
| $162.81K | $125.45K | $20.12K | — | — | — | — | |
| — | — | — | — | $0 | — | $0 | |
| -$7.51M | -$7.97M | -$14.1M | -$14.58M | -$12.09M | -$12.75M | -$4.6M | |
| USD/shares | -$2.43 | -$5.32 | -$17.45 | -$23.00 | -$22.40 | -$29.80 | -$14.80 |
| USD/shares | -$2.43 | -$5.32 | -$17.45 | -$23.00 | -$22.40 | -$29.80 | -$14.80 |
| shares | — | 1.5M | 808.17K | 633.58K | 540.82K | 426.79K | 309.54K |
| shares | — | 1.5M | 808.17K | 633.58K | 540.82K | 426.79K | 309.54K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.12×
EV/EBIT
—
P/E (TTM)
—
Peer median 1.59×
Peer medians compare against the 185 similar-size Biotechnology companies (of 537 listed).
Key facts
CIK
1736243
CUSIP
00510M203
13F (30d)
13 filings
13 filers
Visit website
Investor relations